Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody that has been introduced in the USA in 2009 as a treatment for recurrent high-grade gliomas, has become one of the first-choice therapies for recurrent GBMs, according to National Comprehensive Cancer Network (NCCN) guidelines. Here, VEGFA is linked to central nervous system cancer.